Semmelweis University
- Address
- lock Available on a paid plan
Eye Diseases and Neoplasms
At Semmelweis University, clinical research in ophthalmology and cancer focuses on conditions such as Diabetic Macular Edema and advanced cutaneous squamous cell carcinoma. These studies are designed to assess the safety, tolerability, and early effectiveness of new treatments, while also comparing how well they work against existing or placebo-based approaches.
- Testing a new therapy for Diabetic Macular Edema and evaluating its safety in people with vision-threatening retinal disease
- Studying a treatment option for advanced cutaneous squamous cell carcinoma to better understand safety and preliminary benefit
The research reflects a strong interest in improving treatment options for both retinal disease and skin cancer at the Department of Bor-, Nemikortani es Boronkologiai Klinika.
Skin and Connective Tissue Diseases
Clinical trials at this site also address a range of dermatologic diseases, especially psoriasis and severe inherited skin disorders such as recessive dystrophic epidermolysis bullosa and junctional epidermolysis bullosa. The main goal is to evaluate new immune-targeted and regenerative treatments that may improve symptom control and disease management.
- Assessing new therapies for plaque psoriasis and moderate to severe psoriasis to compare effectiveness and safety
- Exploring cell-based treatment approaches for epidermolysis bullosa, including RDEB and JEB
This area highlights the site’s work in both common inflammatory skin disease and rare genetic skin conditions, with a focus on better long-term outcomes.
Immune System Diseases and Stomatognathic Diseases
Research at Maria Utca 41 includes studies of immune-mediated disease and oral health complications, spanning psoriasis and the prevention of bleeding after dental procedures in patients taking blood-thinning medicines. These trials aim to improve treatment effectiveness and support safer everyday care for patients with complex medical needs.
- Evaluating immune-focused treatments for psoriasis in adults with moderate to severe disease
- Testing an oral solution to help prevent bleeding after tooth extraction in patients using DOACs or VKAs
The portfolio shows a balance between inflammatory disease research and practical studies aimed at reducing complications in dental care.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 of 6 therapeutic areas and 15 of 22 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
- 1Hyloris Developments1active
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 332 other sites in Hungary
Therapeutic Area Benchmark — Hungary
Select a therapeutic area to compare against other sites in Hungary.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Hungary
Market Share
Country: Hungary
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Semmelweis University
lock Showing 1 of 6 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A double-blind, randomized, placebo-controlled, interventional, multicenter, phase III clinical trial to investigate the safety and efficacy of ABCB5-positive mesenchymal stromal cells (ABCB5+ MSCs) on epidermolysis bullosa (EB) | Rheacell GmbH & Co. KG | Phase III | Not Yet Recruiting | Jun 2023 | Jul 2026 |
IMP list
lock Showing 1 of 22 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Allogeneic Skin-Derived Abcb5-Positive Dermal Mesenchymal Stromal Cells | 1 | Unknown | 2023-06-13 | 2023-06-13 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.